Tag: Rapamycin

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO
Articles, Featured

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO

San Antonio-based Rapamycin Holdings, Inc. announced its rebranding Tuesday as Emtora Biosciences with Dr. Carole Spangler Vaughn as its new chief executive officer. Dan Hargrove recruited Spangler Vaughn as his replacement after hiring her as a consultant for the privately-held drug development company about six months ago. The drug company is commercializing a ground-breaking cancer prevention drug, eRapa™, a proprietary reformulation of the generic drug Rapamycin. The changes reflect the company's goal to get the drug through the regulatory approval process faster for a quicker market launch. “I’ve brought drugs to the market before,” Spangler Vaughn told Startups San Antonio. “With my background and experience, I can ask detailed questions about the science, then ask about the dr...
Rapamycin Holdings Treats First Humans in eRapa Clinical Trial
Articles, Featured

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Rapamycin Holdings, Inc. (RHI), a privately-held drug development company, has started treating human patients with its proprietary formulation of a ground-breaking cancer prevention drug. The San Antonio-based company is commercializing eRapa, a novel reformulation of the generic drug Rapamycin. This first human Phase 1b clinical trial of eRapa will treat men with early-stage prostate cancer. Twelve to 24 qualified patients are in the first human trials to establish safety and the optimal dose of eRapa. Michael Liss, M.D., a urologic oncologist at UT Health San Antonio MD Anderson Cancer Center, is leading the clinical trial at the center where the Phase 1b study is being conducted. The cancer center has a long history of testing cancer breakthrough therapies in their early-phase cance...
Five Stories From San Antonio’s Thriving Bioscience Industry
Articles

Five Stories From San Antonio’s Thriving Bioscience Industry

From companies commercializing a cancer prevention drug and urological medical device, to reintroducing transfusion methods and working on a new vaccine and chromosomal abnormalities research, the Health Cell’s annual State of the Industry 2018 event Feb. 6 highlighted San Antonio’s thriving bioscience sector. “This is our fourth annual event,” Health Cell co-founder Beth Eby said. "We aim for a good representation of those ‘who knew?’ stories from San Antonio’s bioscience and healthcare sector." The five stories reflect how innovators in San Antonio are significantly advancing the understanding of critical issues in the life sciences, having a substantial impact on public health, or highlighting pressing health care issues. New Cancer Prevention Drug Boosts Body’s Immune System ...
Rapamycin Holdings, Inc.
Articles, Featured

Rapamycin Holdings, Inc.

San Antonio-based Rapamycin Holdings, Inc. (RHI) is bringing a ground-breaking cancer prevention drug to market. The drug company is commercializing eRapa, a novel, proprietary reformulation of the generic drug Rapamycin. Hailed as the 2009 scientific “Breakthrough of the Year” by Science magazine, eRapa is the first drug proven to extend life span in mammals, on average by 20 percent.  The July 2009 issue of Nature reported that eRapa boosts health and longevity in mice, the first time any drug has extended a mammal’s life span. Rapamycin is an antibiotic derived from microbes discovered in the soils of Easter Island in 1972 and was approved by the Food and Drug Administration (FDA) in 1999 as an immunosuppressant. It has long been used by transplant patients to help fight organ rej...